bluebird bio Inc BLUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
-
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
-
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
-
bluebird bio Announces September Investor Events
-
bluebird bio Announces Receipt of Expected Notices from Nasdaq
-
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
-
bluebird bio Announces Second Quarter 2024 Results Call Date
-
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $0.49
- Day Range
- $0.49–0.51
- 52-Week Range
- $0.46–5.52
- Bid/Ask
- $0.51 / $0.52
- Market Cap
- $99.71 Mil
- Volume/Avg
- 2.4 Mil / 7.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 375
- Website
- https://www.bluebirdbio.com
Comparables
Valuation
|
Metric
|
BLUE
|
FDMT
|
TSHA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 52.57 |
Price/Book Value | 1.78 | 0.91 | 3.79 |
Price/Sales | 1.36 | 24.07 | 31.89 |
Price/Cash Flow | — | — | — |
Price/Earnings
BLUE
FDMT
TSHA
Financial Strength
|
Metric
|
BLUE
|
FDMT
|
TSHA
|
|---|---|---|---|
Quick Ratio | 0.54 | 27.93 | 5.05 |
Current Ratio | 0.68 | 28.48 | 5.22 |
Interest Coverage | −17.45 | — | −52.79 |
Quick Ratio
BLUE
FDMT
TSHA
Profitability
|
Metric
|
BLUE
|
FDMT
|
TSHA
|
|---|---|---|---|
Return on Assets (Normalized) | −48.20% | −18.90% | −40.83% |
Return on Equity (Normalized) | −166.38% | −20.24% | −216.63% |
Return on Invested Capital (Normalized) | −52.99% | −24.42% | −77.31% |
Return on Assets
BLUE
FDMT
TSHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xyykqmtncm | Ttvt | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qlzcspj | Lyyfkl | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pyrktbxmm | Kzykdjg | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ytzvmnsj | Pbyxxd | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Wjwpnsjtz | Wbsmx | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Ybbdhvrm | Msmd | $28.3 Bil | |||
| Moderna Inc
MRNA
| Ghnqxwm | Cxwgs | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bjcbcjtq | Wgrj | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ncxwfmmyk | Ztqvfx | $13.3 Bil | |||
| Incyte Corp
INCY
| Qbddjmj | Ldhpzt | $13.0 Bil |
United States